Last reviewed · How we verify
VX-993
At a glance
| Generic name | VX-993 |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy (PHASE2)
- A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose (PHASE1)
- A Microneurography Study of NaV1.8 Inhibition in Healthy Adults (PHASE1)
- A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults (PHASE1)
- Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults (PHASE1)
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 (PHASE1)
- A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-993 CI brief — competitive landscape report
- VX-993 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI